nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

25.11.2020 | Review

NRF2 in Cardiovascular Diseases: a Ray of Hope!

verfasst von: Ruju Vashi, Bhoomika M. Patel

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Heart failure is a worldwide pandemic influencing 26 million individuals worldwide and is expanding. Imbalanced redox homeostasis in cardiac cells alters the structure and function of the cells, which leads to contractile dysfunction, myocardial hypertrophy, and fibrosis in chronic heart failure. Various targets and agents acting on these such as siRNA, miRNA, interleukin-1, opioids, vasodilators, and SGLT2 inhibitors are being evaluated for heart failure, and nuclear factor erythroid 2–related factor 2 (NRF2) is one of them. NRF2 is a master transcription factor which is expressed in most of the tissues and exhibits a major role in amplification of the antioxidant pathways associated with the enzymes present in myocardium. Increased ROS generation and PI3K-Akt signaling can activate the receptor NRF2. Various in vitro and in vivo and few clinical studies suggested NRF2 may possess a potential for targeting oxidative stress–induced cardiovascular diseases including heart failures. All these studies collectively propose that upregulation of NRF2 will attenuate the increase in hemodynamic stress and provide beneficial role in cardiovascular diseases. The current review shall familiarize readers about the regulations and functions of NRF2. We have also discussed the current evidences suggesting beneficial role of NRF2 activators in heart failure.

Okoshi, M. P., Capalbo, R. V., Romeiro, F. G., & Okoshi, K. (2017). Cardiac cachexia: perspectives for prevention and treatment. Arquivos Brasileiros de Cardiologia, 108, 74. https://doi.org/10.5935/abc.20160142.CrossRefPubMedPubMedCentral

Savarese, G., & Lund, L. H. (2017). Global public health burden of heart failure. Cardiac Failure Review, 3, 7–11. https://doi.org/10.15420/cfr.2016:25:2.CrossRefPubMedPubMedCentral

Writing Group Members, Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., Das, S. R., de Ferranti, S., Després, J.-P., Fullerton, H. J., Howard, V. J., Huffman, M. D., Isasi, C. R., Jiménez, M. C., Judd, S. E., Kissela, B. M., Lichtman, J. H., Lisabeth, L. D., Liu, S., Mackey, R. H., Magid, D. J., McGuire, D. K., Mohler, E. R., Moy, C. S., Muntner, P., Mussolino, M. E., Nasir, K., Neumar, R. W., Nichol, G., Palaniappan, L., Pandey, D. K., Reeves, M. J., Rodriguez, C. J., Rosamond, W., Sorlie, P. D., Stein, J., Towfighi, A., Turan, T. N., Virani, S. S., Woo, D., Yeh, R. W., Turner, M. B., American Heart Association Statistics Committee, & Stroke Statistics Subcommittee. (2016). Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation, 133, e38–e360. https://doi.org/10.1161/CIR.0000000000000350.CrossRef

Pamela A.Harvey, Leslie A.Leinwand, 2014. Cardiac atrophy and remodeling. Cellular and Molecular Pathobiology of Cardiovascular Disease 37–50. https://doi.org/10.1016/B978-0-12-405206-2.00003-X.

Genth-Zotz, S., von Haehling, S., Bolger, A. P., Kalra, P. R., Wensel, R., Coats, A. J. S., & Anker, S. D. (2002). Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. The American Journal of Cardiology, 90, 1226–1230. https://doi.org/10.1016/s0002-9149(02)02839-4.CrossRefPubMed

Wei, J. Y. (1992). Age and the cardiovascular system. The New England Journal of Medicine, 327, 1735–1739. https://doi.org/10.1056/NEJM199212103272408.CrossRefPubMed

Yoshida, T., & Delafontaine, P. (2015). Mechanisms of cachexia in chronic disease states. The American Journal of the Medical Sciences, 350, 250–256. https://doi.org/10.1097/MAJ.0000000000000511.CrossRefPubMedPubMedCentral

Raghunathan, S., & Patel, B. M. (2013). Therapeutic implications of small interfering RNA in cardiovascular diseases. Fundamental & Clinical Pharmacology, 27, 1–20. https://doi.org/10.1111/j.1472-8206.2012.01051.x.CrossRef

Wong, L. L., Wang, J., Liew, O. W., Richards, A. M., & Chen, Y.-T. (2016). MicroRNA and heart failure. International Journal of Molecular Sciences, 17. https://doi.org/10.3390/ijms17040502.

10.

Patel B. M. (2019). Histone deacetylases and oxidative stress: Role in diabetic cardiomyopathy. In S. Chakraborti, N. S. Dhalla, M. Dixit, N. K. Ganguly (Eds.), Oxidative Stress in Heart Diseases (pp. 413–425). New York: Springer.

11.

Patel, R. B., & Shah, S. J. (2019). Drug targets for heart failure with preserved ejection fraction: a mechanistic approach and review of contemporary clinical trials. Annual Review of Pharmacology and Toxicology, 59, 41–63. https://doi.org/10.1146/annurev-pharmtox-010818-021136.CrossRefPubMed

12.

Rawal, H., & Patel, B. M. (2018). Opioids in cardiovascular disease: therapeutic options. Journal of Cardiovascular Pharmacology and Therapeutics, 23, 279–291. https://doi.org/10.1177/1074248418757009.CrossRefPubMed

13.

Armstrong, P. W., Roessig, L., Patel, M. J., Anstrom, K. J., Butler, J., Voors, A. A., Lam, C. S. P., Ponikowski, P., Temple, T., Pieske, B., Ezekowitz, J., Hernandez, A. F., Koglin, J., & O’Connor, C. M. (2018). A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial. JACC Heart Fail, 6, 96–104. https://doi.org/10.1016/j.jchf.2017.08.013.CrossRefPubMed

14.

Baker, W. L., Buckley, L. F., Kelly, M. S., Bucheit, J. D., Parod, E. D., Brown, R., Carbone, S., Abbate, A., & Dixon, D. L. (2017). Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 6, e005686. https://doi.org/10.1161/JAHA.117.005686.CrossRef

15.

Ma, Q. (2013). Role of nrf2 in oxidative stress and toxicity. Annual Review of Pharmacology and Toxicology, 53, 401–426. https://doi.org/10.1146/annurev-pharmtox-011112-140320.CrossRefPubMedPubMedCentral

16.

Tan, Y., Ichikawa, T., Li, J., Si, Q., Yang, H., Chen, X., Goldblatt, C. S., Meyer, C. J., Li, X., Cai, L., & Cui, T. (2011). Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes, 60, 625–633. https://doi.org/10.2337/db10-1164.CrossRefPubMedPubMedCentral

17.

Tian, C., Gao, L., Zimmerman, M. C., & Zucker, I. H. (2018). Myocardial infarction-induced microRNA-enriched exosomes contribute to cardiac Nrf2 dysregulation in chronic heart failure. American Journal of Physiology. Heart and Circulatory Physiology, 314, H928–H939. https://doi.org/10.1152/ajpheart.00602.2017.CrossRefPubMedPubMedCentral

18.

Venugopal, R., & Jaiswal, A. K. (1998). Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene, 17, 3145–3156. https://doi.org/10.1038/sj.onc.1202237.CrossRefPubMed

19.

Venugopal, R., & Jaiswal, A. K. (1996). Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proceedings of the National Academy of Sciences of the United States of America, 93, 14960–14965. https://doi.org/10.1073/pnas.93.25.14960.CrossRefPubMedPubMedCentral

20.

Cervantes Gracia, K., Llanas-Cornejo, D., & Husi, H. (2017). CVD and oxidative stress. Journal of Clinical Medicine, 6. https://doi.org/10.3390/jcm6020022.

21.

Kim, M., Han, C., & Lee, M.-Y. (2014). NADPH oxidase and the cardiovascular toxicity associated with smoking. Toxicology Research, 30, 149–157. https://doi.org/10.5487/TR.2014.30.3.149.CrossRef

22.

Chen, X.-L., Varner, S. E., Rao, A. S., Grey, J. Y., Thomas, S., Cook, C. K., Wasserman, M. A., Medford, R. M., Jaiswal, A. K., & Kunsch, C. (2003). Laminar flow induction of antioxidant response element-mediated genes in endothelial cells. A novel anti-inflammatory mechanism. The Journal of Biological Chemistry, 278, 703–711. https://doi.org/10.1074/jbc.M203161200.CrossRefPubMed

23.

Satta, S., Mahmoud, A. M., Wilkinson, F. L., Yvonne Alexander, M., & White, S. J. (2017). The role of Nrf2 in cardiovascular function and disease. Oxidative Medicine and Cellular Longevity, 2017, 9237263. https://doi.org/10.1155/2017/9237263.CrossRefPubMedPubMedCentral

24.

Grossman, E. (2008). Does increased oxidative stress cause hypertension? Diabetes Care, 31(Suppl 2), S185–S189. https://doi.org/10.2337/dc08-s246.CrossRefPubMed

25.

Lopes, R. A., Neves, K. B., Tostes, R. C., Montezano, A. C., & Touyz, R. M. (2015). Downregulation of nuclear factor erythroid 2-related factor and associated antioxidant genes contributes to redox-sensitive vascular dysfunction in hypertension. Hypertension (Dallas, Tex. : 1979), 66, 1240–1250. https://doi.org/10.1161/HYPERTENSIONAHA.115.06163.CrossRef

26.

Robledinos-Antón, N., Fernández-Ginés, R., Manda, G., & Cuadrado, A. (2019). Activators and inhibitors of NRF2: a review of their potential for clinical development [WWW document]. Oxidative Medicine and Cellular Longevity, 2019, 9372182. https://doi.org/10.1155/2019/9372182.CrossRefPubMedPubMedCentral

27.

Li, R., Jia, Z., & Zhu, H. (2019a). Regulation of Nrf2 signaling. Reactive Oxygen Species (Apex, N.C.), 8, 312–322.

28.

Li, L., Luo, W., Qian, Y., Zhu, W., Qian, J., Li, J., Jin, Y., Xu, X., & Liang, G. (2019b). Luteolin protects against diabetic cardiomyopathy by inhibiting NF-κB-mediated inflammation and activating the Nrf2-mediated antioxidant responses. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology, 59, 152774. https://doi.org/10.1016/j.phymed.2018.11.034.CrossRef

29.

Harder, B., Jiang, T., Wu, T., Tao, S., de la Vega, M. R., Tian, W., Chapman, E., & Zhang, D. D. (2015). Molecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease intervention. Biochemical Society Transactions, 43, 680–686. https://doi.org/10.1042/BST20150020.CrossRefPubMedPubMedCentral

30.

Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004). Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Molecular and Cellular Biology, 24, 7130–7139. https://doi.org/10.1128/MCB.24.16.7130-7139.2004.CrossRefPubMedPubMedCentral

31.

Zhang, D. D., & Hannink, M. (2003). Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Molecular and Cellular Biology, 23, 8137–8151. https://doi.org/10.1128/mcb.23.22.8137-8151.2003.CrossRefPubMedPubMedCentral

32.

Miao, W., Hu, L., Scrivens, P. J., & Batist, G. (2005). Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes. The Journal of Biological Chemistry, 280, 20340–20348. https://doi.org/10.1074/jbc.M412081200.CrossRefPubMed

33.

Cuadrado, A., Martín-Moldes, Z., Ye, J., & Lastres-Becker, I. (2014). Transcription factors NRF2 and NF-κB are coordinated effectors of the Rho family, GTP-binding protein RAC1 during inflammation. The Journal of Biological Chemistry, 289, 15244–15258. https://doi.org/10.1074/jbc.M113.540633.CrossRefPubMedPubMedCentral

34.

DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., Scrimieri, F., Winter, J. M., Hruban, R. H., Iacobuzio-Donahue, C., Kern, S. E., Blair, I. A., & Tuveson, D. A. (2011). Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature, 475, 106–109. https://doi.org/10.1038/nature10189.CrossRefPubMedPubMedCentral

35.

Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012). Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell, 22, 66–79. https://doi.org/10.1016/j.ccr.2012.05.016.CrossRefPubMed

36.

Wakabayashi, N., Skoko, J. J., Chartoumpekis, D. V., Kimura, S., Slocum, S. L., Noda, K., Palliyaguru, D. L., Fujimuro, M., Boley, P. A., Tanaka, Y., Shigemura, N., Biswal, S., Yamamoto, M., & Kensler, T. W. (2014). Notch-Nrf2 axis: regulation of Nrf2 gene expression and cytoprotection by notch signaling. Molecular and Cellular Biology, 34, 653–663. https://doi.org/10.1128/MCB.01408-13.CrossRefPubMedPubMedCentral

37.

Faraonio, R., Vergara, P., Di Marzo, D., Pierantoni, M. G., Napolitano, M., Russo, T., & Cimino, F. (2006). p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. The Journal of Biological Chemistry, 281, 39776–39784. https://doi.org/10.1074/jbc.M605707200.CrossRefPubMed

38.

Moi, P., Chan, K., Asunis, I., Cao, A., & Kan, Y. W. (1994). Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proceedings of the National Academy of Sciences of the United States of America, 91, 9926–9930. https://doi.org/10.1073/pnas.91.21.9926.CrossRefPubMedPubMedCentral

39.

Holmström, K. M., Baird, L., Zhang, Y., Hargreaves, I., Chalasani, A., Land, J. M., Stanyer, L., Yamamoto, M., Dinkova-Kostova, A. T., & Abramov, A. Y. (2013). Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration. Biology Open, 2, 761–770. https://doi.org/10.1242/bio.20134853.CrossRefPubMedPubMedCentral

40.

Kwak, M.-K., Wakabayashi, N., Greenlaw, J. L., Yamamoto, M., & Kensler, T. W. (2003). Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Molecular and Cellular Biology, 23, 8786–8794. https://doi.org/10.1128/mcb.23.23.8786-8794.2003.CrossRefPubMedPubMedCentral

41.

Malhotra, D., Portales-Casamar, E., Singh, A., Srivastava, S., Arenillas, D., Happel, C., Shyr, C., Wakabayashi, N., Kensler, T. W., Wasserman, W. W., & Biswal, S. (2010). Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Research, 38, 5718–5734. https://doi.org/10.1093/nar/gkq212.CrossRefPubMedPubMedCentral

42.

Canning, P., Sorrell, F. J., & Bullock, A. N. (2015). Structural basis of Keap1 interactions with Nrf2. Free Radical Biology & Medicine, 88, 101. https://doi.org/10.1016/j.freeradbiomed.2015.05.034.CrossRef

43.

Motohashi, H., Katsuoka, F., Engel, J. D., & Yamamoto, M. (2004). Small Maf proteins serve as transcriptional cofactors for keratinocyte differentiation in the Keap1–Nrf2 regulatory pathway. Proceedings of the National Academy of Sciences of the United States of America, 101, 6379–6384. https://doi.org/10.1073/pnas.0305902101.CrossRefPubMedPubMedCentral

44.

Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., Yamamoto, M., & Nabeshima, Y. (1997). An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochemical and Biophysical Research Communications, 236, 313–322. https://doi.org/10.1006/bbrc.1997.6943.CrossRefPubMed

45.

Wafi, A. M., Yu, L., Gao, L., & Zucker, I. H. (2019b). Exercise training upregulates Nrf2 protein in the rostral ventrolateral medulla of mice with heart failure. Journal of Applied Physiology (Bethesda, Md.: 1985), 127, 1349–1359. https://doi.org/10.1152/japplphysiol.00469.2019.CrossRef

46.

Ma, A., Hong, J., Shanks, J., Rudebush, T., Yu, L., Hackfort, B. T., Wang, H., Zucker, I. H., & Gao, L. (2019). Upregulating Nrf2 in the RVLM ameliorates sympatho-excitation in mice with chronic heart failure. Free Radical Biology & Medicine, 141, 84–92. https://doi.org/10.1016/j.freeradbiomed.2019.06.002.CrossRef

47.

Strom, J., & Chen, Q. M. (2017). Loss of Nrf2 promotes rapid progression to heart failure following myocardial infarction. Toxicology and Applied Pharmacology, 327, 52–58. https://doi.org/10.1016/j.taap.2017.03.025.CrossRefPubMed

48.

Kazakov, A., Hall, R. A., Werner, C., Meier, T., Trouvain, A., Rodionycheva, S., Nickel, A., Lammert, F., Maack, C., Böhm, M., & Laufs, U. (2018). Raf kinase inhibitor protein mediates myocardial fibrosis under conditions of enhanced myocardial oxidative stress. Basic Research in Cardiology, 113, 42. https://doi.org/10.1007/s00395-018-0700-3.CrossRefPubMedPubMedCentral

49.

Erkens, R., Kramer, C. M., Lückstädt, W., Panknin, C., Krause, L., Weidenbach, M., Dirzka, J., Krenz, T., Mergia, E., Suvorava, T., Kelm, M., & Cortese-Krott, M. M. (2015). Left ventricular diastolic dysfunction in Nrf2 knock out mice is associated with cardiac hypertrophy, decreased expression of SERCA2a, and preserved endothelial function. Free Radical Biology & Medicine, 89, 906–917. https://doi.org/10.1016/j.freeradbiomed.2015.10.409.CrossRef

50.

Tian, C., Gao, L., Zhang, A., Hackfort, B. T., & Zucker, I. H. (2019). Therapeutic effects of Nrf2 activation by bardoxolone methyl in chronic heart failure. The Journal of Pharmacology and Experimental Therapeutics, 371, 642–651. https://doi.org/10.1124/jpet.119.261792.CrossRefPubMedPubMedCentral

51.

Konishi, M., Baumgarten, A., Ishida, J., Saitoh, M., Anker, S. D., & Springer, J. (2016). Protein levels in Keap1-Nrf2 system in human failing heart. International Journal of Cardiology, 225, 62–64. https://doi.org/10.1016/j.ijcard.2016.09.128.CrossRefPubMed

52.

Li, H.-Q., Wu, Y.-B., Yin, C.-S., Chen, L., Zhang, Q., & Hu, L.-Q. (2016). Obestatin attenuated doxorubicin-induced cardiomyopathy via enhancing long noncoding Mhrt RNA expression. Biomed. Pharmacother. Biomedecine Pharmacother., 81, 474–481. https://doi.org/10.1016/j.biopha.2016.04.017.CrossRef

53.

Waza, A. A., Hamid, Z., Bhat, S. A., Shah, N. U. D., Bhat, M., & Ganai, B. (2018). Relaxin protects cardiomyocytes against hypoxia-induced damage in in-vitro conditions: involvement of Nrf2/HO-1 signaling pathway. Life Sciences, 213, 25–31. https://doi.org/10.1016/j.lfs.2018.08.059.CrossRefPubMed

54.

Shinjo, T., Tanaka, T., Okuda, H., Kawaguchi, A. T., Oh-Hashi, K., Terada, Y., Isonishi, A., Morita-Takemura, S., Tatsumi, K., Kawaguchi, M., & Wanaka, A. (2018). Propofol induces nuclear localization of Nrf2 under conditions of oxidative stress in cardiac H9c2 cells. PLoS One, 13, e0196191. https://doi.org/10.1371/journal.pone.0196191.CrossRefPubMedPubMedCentral

55.

Bai, Y., Chen, Q., Sun, Y.-P., Wang, X., Lv, L., Zhang, L.-P., Liu, J.-S., Zhao, S., & Wang, X.-L. (2017). Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation. Cardiovascular Therapeutics, 35. https://doi.org/10.1111/1755-5922.12277.

56.

Guan, P., Liang, Y., & Wang, N. (2018). Fasudil alleviates pressure overload-induced heart failure by activating Nrf2-mediated antioxidant responses. Journal of Cellular Biochemistry, 119, 6452–6460. https://doi.org/10.1002/jcb.26662.CrossRefPubMed

57.

Sharma, A., Parikh, M., Shah, H., & Gandhi, T. (2020). Modulation of Nrf2 by quercetin in doxorubicin-treated rats. Heliyon, 6, e03803. https://doi.org/10.1016/j.heliyon.2020.e03803.CrossRefPubMedPubMedCentral

58.

Liu, Y., Li, L.-N., Guo, S., Zhao, X.-Y., Liu, Y.-Z., Liang, C., Tu, S., Wang, D., Li, L., Dong, J.-Z., Gao, L., & Yang, H.-B. (2018). Melatonin improves cardiac function in a mouse model of heart failure with preserved ejection fraction. Redox Biology, 18, 211–221. https://doi.org/10.1016/j.redox.2018.07.007.CrossRefPubMedPubMedCentral

59.

Wafi, A. M., Hong, J., Rudebush, T. L., Yu, L., Hackfort, B., Wang, H., Schultz, H. D., Zucker, I. H., & Gao, L. (2019a). Curcumin improves exercise performance of mice with coronary artery ligation-induced HFrEF: Nrf2 and antioxidant mechanisms in skeletal muscle. Journal of Applied Physiology (Bethesda, Md.: 1985), 126, 477–486. https://doi.org/10.1152/japplphysiol.00654.2018.CrossRef

60.

Wang, H., Lai, Y., Mathis, B. J., Wang, W., Li, S., Qu, C., Li, B., Shao, L., Song, H., Janicki, J. S., Sun, S.-C., Wang, X. L., Tang, D., & Cui, T. (2015). Deubiquitinating enzyme CYLD mediates pressure overload-induced cardiac maladaptive remodeling and dysfunction via downregulating Nrf2. Journal of Molecular and Cellular Cardiology, 84, 143–153. https://doi.org/10.1016/j.yjmcc.2015.04.012.CrossRefPubMed

61.

Jing, L., Shao, J., Sun, W., Lan, T., Jia, Z., Ma, H., & Wang, H. (2020). Protective effects of two novel nitronyl nitroxide radicals on heart failure induced by hypobaric hypoxia. Life Sciences, 248, 116481. https://doi.org/10.1016/j.lfs.2019.05.037.CrossRefPubMed

62.

Zhang, B., Zhang, J., Zhang, C., Zhang, X., Ye, J., Kuang, S., Sun, G., & Sun, X. (2018). Notoginsenoside R1 protects against diabetic cardiomyopathy through activating estrogen receptor α and its downstream signaling. Frontiers in Pharmacology, 9, 1227. https://doi.org/10.3389/fphar.2018.01227.CrossRefPubMedPubMedCentral

63.

Zhang, L., Guo, Z., Wang, Y., Geng, J., & Han, S. (2019). The protective effect of kaempferol on heart via the regulation of Nrf2, NF-κβ, and PI3K/Akt/GSK-3β signaling pathways in isoproterenol-induced heart failure in diabetic rats. Drug Development Research, 80, 294–309. https://doi.org/10.1002/ddr.21495.CrossRefPubMed

64.

Gao, L., Liu, Y., Guo, S., Xiao, L., Wu, L., Wang, Z., Liang, C., Yao, R., & Zhang, Y. (2018). LAZ3 protects cardiac remodeling in diabetic cardiomyopathy via regulating miR-21/PPARa signaling. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1864, 3322–3338. https://doi.org/10.1016/j.bbadis.2018.07.019.CrossRefPubMed

65.

Bubb, K. J., Kok, C., Tang, O., Rasko, N. B., Birgisdottir, A. B., Hansen, T., Ritchie, R., Bhindi, R., Reisman, S. A., Meyer, C., Ward, K., Karimi Galougahi, K., & Figtree, G. A. (2017). The NRF2 activator DH404 attenuates adverse ventricular remodeling post-myocardial infarction by modifying redox signalling. Free Radical Biology & Medicine, 108, 585–594. https://doi.org/10.1016/j.freeradbiomed.2017.04.027.CrossRef

66.

Lacerda, D., Ortiz, V., Türck, P., Campos-Carraro, C., Zimmer, A., Teixeira, R., Bianchi, S., de Castro, A. L., Schenkel, P. C., Belló-Klein, A., Bassani, V. L., & da Rosa Araujo, A. S. (2018). Stilbenoid pterostilbene complexed with cyclodextrin preserves left ventricular function after myocardial infarction in rats: possible involvement of thiol proteins and modulation of phosphorylated GSK-3β. Free Radical Research, 52, 988–999. https://doi.org/10.1080/10715762.2018.1506115.CrossRefPubMed

67.

Shimizu, Y., Nicholson, C. K., Lambert, J. P., Barr, L. A., Kuek, N., Herszenhaut, D., Tan, L., Murohara, T., Hansen, J. M., Husain, A., Naqvi, N., & Calvert, J. W. (2016). Sodium sulfide attenuates ischemic-induced heart failure by enhancing proteasomal function in an Nrf2-dependent manner. Circulation. Heart Failure, 9, e002368. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002368.CrossRefPubMedPubMedCentral

68.

Liu, C., Wu, Q.-Q., Cai, Z.-L., Xie, S.-Y., Duan, M.-X., Xie, Q.-W., Yuan, Y., Deng, W., & Tang, Q.-Z. (2019). Zingerone attenuates aortic banding-induced cardiac remodelling via activating the eNOS/Nrf2 pathway. Journal of Cellular and Molecular Medicine, 23, 6466–6478. https://doi.org/10.1111/jcmm.14540.CrossRefPubMedPubMedCentral

69.

Goh, K. Y., He, L., Song, J., Jinno, M., Rogers, A. J., Sethu, P., Halade, G. V., Rajasekaran, N. S., Liu, X., Prabhu, S. D., Darley-Usmar, V., Wende, A. R., & Zhou, L. (2019). Mitoquinone ameliorates pressure overload-induced cardiac fibrosis and left ventricular dysfunction in mice. Redox Biology, 21, 101100. https://doi.org/10.1016/j.redox.2019.101100.CrossRefPubMedPubMedCentral

70.

Zeng, B., Liu, L., Liao, X., Zhang, C., & Ruan, H. (2019). Thyroid hormone protects cardiomyocytes from H2O2-induced oxidative stress via the PI3K-AKT signaling pathway. Experimental Cell Research, 380, 205–215. https://doi.org/10.1016/j.yexcr.2019.05.003.CrossRefPubMed

71.

Shao, M., Zhuo, C., Jiang, R., Chen, G., Shan, J., Ping, J., Tian, H., Wang, L., Lin, C., & Hu, L. (2017). Protective effect of hydrogen sulphide against myocardial hypertrophy in mice. Oncotarget, 8, 22344–22352. https://doi.org/10.18632/oncotarget.15765.CrossRefPubMedPubMedCentral

72.

Cai, S.-A., Hou, N., Zhao, G.-J., Liu, X.-W., He, Y.-Y., Liu, H.-L., Hua, Y.-Q., Li, L.-R., Huang, Y., Ou, C.-W., Luo, C.-F., & Chen, M.-S. (2018). Nrf2 is a key regulator on puerarin preventing cardiac fibrosis and upregulating metabolic enzymes UGT1A1 in rats. Frontiers in Pharmacology, 9, 540. https://doi.org/10.3389/fphar.2018.00540.CrossRefPubMedPubMedCentral

73.

Du, Y., Han, J., Zhang, H., Xu, J., Jiang, L., & Ge, W. (2019). Kaempferol prevents against Ang II-induced cardiac remodeling through attenuating Ang II-induced inflammation and oxidative stress. Journal of Cardiovascular Pharmacology, 74, 326–335. https://doi.org/10.1097/FJC.0000000000000713.CrossRefPubMedPubMedCentral

74.

Nie, P., Meng, F., Zhang, J., Wei, X., & Shen, C. (2019). Astragaloside IV exerts a myocardial protective effect against cardiac hypertrophy in rats, partially via activating the Nrf2/HO-1 signaling pathway. Oxidative Medicine and Cellular Longevity, 2019, 4625912. https://doi.org/10.1155/2019/4625912.CrossRefPubMedPubMedCentral

75.

Hou, X., Fu, M., Cheng, B., Kang, Y., & Xie, D. (2019). Galanthamine improves myocardial ischemia-reperfusion-induced cardiac dysfunction, endoplasmic reticulum stress-related apoptosis, and myocardial fibrosis by suppressing AMPK/Nrf2 pathway in rats. Annals of Translational Medicine: Home, 7, 634. https://doi.org/10.21037/atm.2019.10.108.CrossRef

76.

Donnarumma, E., Bhushan, S., Bradley, J. M., Otsuka, H., Donnelly, E. L., Lefer, D. J., & Islam, K. N. (2016). Nitrite therapy ameliorates myocardial dysfunction via H2S and nuclear factor-erythroid 2-related factor 2 (Nrf2)-dependent signaling in chronic heart failure. Journal of the American Heart Association, 5. https://doi.org/10.1161/JAHA.116.003551.

77.

Li, Y., & Zhang, H. (2017). Soybean isoflavones ameliorate ischemic cardiomyopathy by activating Nrf2-mediated antioxidant responses. Food & Function, 8, 2935–2944. https://doi.org/10.1039/c7fo00342k.CrossRef

78.

Chen, Q. M., & Maltagliati, A. J. (2018). Nrf2 at the heart of oxidative stress and cardiac protection. Physiological Genomics, 50, 77–97. https://doi.org/10.1152/physiolgenomics.00041.2017.CrossRefPubMed

79.

Choi, H.-M., Park, M.-S., & Youn, J.-C. (2019). Update on heart failure management and future directions. The Korean Journal of Internal Medicine, 34, 11–43. https://doi.org/10.3904/kjim.2018.428.CrossRefPubMed

80.

Kahroba, H., & Davatgaran-Taghipour, Y. (2020). Exosomal Nrf2: From anti-oxidant and anti-inflammation response to wound healing and tissue regeneration in aged-related diseases. Biochimie, 171–172, 103–109. https://doi.org/10.1016/j.biochi.2020.02.011.CrossRefPubMed

81.

Appendino, G., Belcaro, G., Cornelli, U., Luzzi, R., Togni, S., Dugall, M., Cesarone, M. R., Feragalli, B., Ippolito, E., Errichi, B. M., Pellegrini, L., Ledda, A., Ricci, A., Bavera, P., Hosoi, M., Stuard, S., Corsi, M., Errichi, S., & Gizzi, G. (2011). Potential role of curcumin phytosome (Meriva) in controlling the evolution of diabetic microangiopathy. A Pilot Study. Panminerva Medica, 53, 43–49.PubMed

82.

Ooi, B. K., Chan, K.-G., Goh, B. H., & Yap, W. H. (2018). The role of natural products in targeting cardiovascular diseases via Nrf2 pathway: novel molecular mechanisms and therapeutic approaches. Frontiers in Pharmacology, 9. https://doi.org/10.3389/fphar.2018.01308.

83.

Qian, Y., Zhong, P., Liang, D., Xu, Z., Skibba, M., Zeng, C., Li, X., Wei, T., Wu, L., & Liang, G. (2015). A newly designed curcumin analog Y20 mitigates cardiac injury via anti-inflammatory and anti-oxidant actions in obese rats. PLoS One, 10, e0120215. https://doi.org/10.1371/journal.pone.0120215.CrossRefPubMedPubMedCentral

84.

Xin, Y., Bai, Y., Jiang, X., Zhou, S., Wang, Y., Wintergerst, K. A., Cui, T., Ji, H., Tan, Y., & Cai, L. (2018). Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway. Redox Biology, 15, 405–417. https://doi.org/10.1016/j.redox.2017.12.016.CrossRefPubMedPubMedCentral

85.

Tan, Y., Wan, H.-H., Sun, M.-M., Zhang, W.-J., Dong, M., Ge, W., Ren, J., Peng, H., 2020. Cardamonin protects against lipopolysaccharide-induced myocardial contractile dysfunction in mice through Nrf2-regulated mechanism. Acta Pharmacologica Sinica https://doi.org/10.1038/s41401-020-0397-3.

86.

Patel, B. M., & Mehta, A. A. (2012). Aldosterone and angiotensin: role in diabetes and cardiovascular diseases. European Journal of Pharmacology, 697, 1–12. https://doi.org/10.1016/j.ejphar.2012.09.034.CrossRefPubMed

87.

Patel, B. M., & Mehta, A. A. (2013). Choice of anti-hypertensive agents in diabetic subjects. Diabetes & Vascular Disease Research, 10, 385–396. https://doi.org/10.1177/1479164113485250.CrossRef

88.

Goyal, B. R., Solanki, N., Goyal, R. K., & Mehta, A. A. (2009). Investigation into the cardiac effects of spironolactone in the experimental model of type 1 diabetes. Journal of Cardiovascular Pharmacology, 54, 502–509. https://doi.org/10.1097/FJC.0b013e3181be75cc.CrossRefPubMed

89.

Goyal, B. R., Mesariya, P., Goyal, R. K., & Mehta, A. A. (2008). Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats. Molecular and Cellular Biochemistry, 314, 123–131. https://doi.org/10.1007/s11010-008-9772-y.CrossRefPubMed

90.

Patel, B. M., Kakadiya, J., Goyal, R. K., & Mehta, A. A. (2013). Effect of spironolactone on cardiovascular complications associated with type-2 diabetes in rats. Experimental and Clinical Endocrinology & Diabetes: Official Journal, German Society of Endocrinology and German Diabetes Association, 121, 441–447. https://doi.org/10.1055/s-0033-1345168.CrossRef

91.

Goyal, B. R., Parmar, K., Goyal, R. K., & Mehta, A. A. (2011). Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats. Pharmacological Report, 63, 956–966. https://doi.org/10.1016/s1734-1140(11)70611-9.CrossRef

92.

Patel, B. M., Agarwal, S. S., & Bhadada, S. V. (2012). Perindopril protects against streptozotocin-induced hyperglycemic myocardial damage/alterations. Human & Experimental Toxicology, 31, 1132–1143. https://doi.org/10.1177/0960327112446817.CrossRef

93.

Patel, B. M., & Bhadada, S. V. (2014). Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril. Clinical and Experimental Hypertens, 1993(36), 340–347. https://doi.org/10.3109/10641963.2013.827699.CrossRef

94.

Raghunathan, S., Tank, P., Bhadada, S., & Patel, B. (2014). Evaluation of buspirone on streptozotocin induced type 1 diabetes and its associated complications. BioMed Research International, 2014, 948427. https://doi.org/10.1155/2014/948427.CrossRefPubMedPubMedCentral

95.

Patel, B. M., Raghunathan, S., & Porwal, U. (2014). Cardioprotective effects of magnesium valproate in type 2 diabetes mellitus. European Journal of Pharmacology, 728, 128–134. https://doi.org/10.1016/j.ejphar.2014.01.063.CrossRefPubMed

97.

Rabadiya, S., Bhadada, S., Dudhrejiya, A., Vaishnav, D., & Patel, B. (2018). Magnesium valproate ameliorates type 1 diabetes and cardiomyopathy in diabetic rats through estrogen receptors. Biomedicine & Pharmacotherapy, 97, 919–927. https://doi.org/10.1016/j.biopha.2017.10.137.CrossRef

98.

Steele, M. L., Fuller, S., Patel, M., Kersaitis, C., Ooi, L., & Münch, G. (2013). Effect of Nrf2 activators on release of glutathione, cysteinylglycine and homocysteine by human U373 astroglial cells. Redox Biology, 1, 441–445. https://doi.org/10.1016/j.redox.2013.08.006.CrossRefPubMedPubMedCentral

99.

Frangogiannis, N. G. (2015). Pathophysiology of myocardial infarction. Comprehensive Physiology, 5, 1841–1875. https://doi.org/10.1002/cphy.c150006.CrossRefPubMed

100.

Lu, L., Liu, M., Sun, R., Zheng, Y., & Zhang, P. (2015). Myocardial infarction: symptoms and treatments. Cell Biochemistry and Biophysics, 72, 865–867. https://doi.org/10.1007/s12013-015-0553-4.CrossRefPubMed

101.

Cowled, P., & Fitridge, R. (2011). Pathophysiology of reperfusion injury. In R. Fitridge & M. Thompson (Eds.), Mechanisms of vascular disease: a reference book for vascular specialists. Adelaide: University of Adelaide Press.

102.

Samak, M., Fatullayev, J., Sabashnikov, A., Zeriouh, M., Schmack, B., Farag, M., Popov, A.-F., Dohmen, P. M., Choi, Y.-H., Wahlers, T., & Weymann, A. (2016). Cardiac hypertrophy: an introduction to molecular and cellular basis. Medical Science Monitor Basic Research, 22, 75–79. https://doi.org/10.12659/MSMBR.900437.CrossRefPubMedPubMedCentral

103.

Raghunathan, S., Goyal, R. K., & Patel, B. M. (2017). Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy. Can J Physiol Pharmacol, 95(3), 260–267.CrossRef

104.

Sharma, B., Chaube, U., & Patel, B. M. (2019). Beneficial effect of silymarin in pressure overload induced experimental cardiac hypertrophy. Cardiovasc Toxicology 19(1), 23–35.

105.

Patel, B. M. (2018). Sodium butyrate controls cardiac hypertrophy in experimental models of rats. Cardiovasc Toxicology1 18(1), 1–8.

106.

Chin, M. P., Bakris, G. L., Block, G. A., Chertow, G. M., Goldsberry, A., Inker, L. A., Heerspink, H. J. L., O’Grady, M., Pergola, P. E., Wanner, C., Warnock, D. G., & Meyer, C. J. (2018). Bardoxolone methyl improves kidney function in patients with chronic kidney disease stage 4 and type 2 diabetes: post-hoc analyses from bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes study. American Journal of Nephrology, 47, 40–47. https://doi.org/10.1159/000486398.CrossRefPubMed

107.

Qingyun, Q., Chen, Q., Ting, N., Huimei, Z., Lei, Q., Linmao, L., Wang, X., Mitzi, N., Prakash, N., Janicki, J. S., Li, W. X., & Taixing, C. (2016). Nrf2-mediated cardiac maladaptive remodeling and dysfunction in a setting of autophagy insufficiency. Hypertension, 67, 107–117. https://doi.org/10.1161/HYPERTENSIONAHA.115.06062.CrossRef

108.

Berenice, B., Nam, C., Fen, Y., Amir, R., Orozco, L. D., Wei, G. K., Wang, X., Castellani, L. W., Karen, R., Lusis, A. J., & Araujo, J. A. (2011). NF-E2–related factor 2 promotes atherosclerosis by effects on plasma lipoproteins and cholesterol transport that overshadow antioxidant protection. Arteriosclerosis, Thrombosis, and Vascular Biology, 31, 58–66. https://doi.org/10.1161/ATVBAHA.110.210906.CrossRef

109.

Sussan, T. E., Jun, J., Thimmulappa, R., Bedja, D., Antero, M., Gabrielson, K. L., Polotsky, V. Y., & Biswal, S. (2008). Disruption of Nrf2, a key inducer of antioxidant defenses, attenuates ApoE-mediated atherosclerosis in mice. PLoS One, 3, e3791. https://doi.org/10.1371/journal.pone.0003791.CrossRefPubMedPubMedCentral

110.

Kopacz, A., Kloska, D., Forman, H. J., Jozkowicz, A., & Grochot-Przeczek, A. (2020). Beyond repression of Nrf2: an update on Keap1. Free Radical Biology & Medicine, 157, 63–74. https://doi.org/10.1016/j.freeradbiomed.2020.03.023.CrossRef

111.

Chen, C., Huo, R., Tong, Y., Sheng, Y., Liu, H.-B., Gao, X., Nakajima, O., Yang, B.-F., & Dong, D.-L. (2011). Systemic heme oxygenase-1 transgenic overexpression aggravates pressure overload-induced cardiac hypertrophy in mice. Cellular Physiology & Biochemistry - International Journal of Experimental Cellular Physiology, Biochemistry and Pharmacology, 28, 25–32. https://doi.org/10.1159/000331710.CrossRef

112.

Jirkovsky, E., Popelová, O., Kriváková-Stanková, P., Vávrová, A., Hroch, M., Hasková, P., Brcáková-Dolezelová, E., Micuda, S., Adamcová, M., Simůnek, T., Cervinková, Z., Gersl, V., & Sterba, M. (2012). Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways. The Journal of Pharmacology and Experimental Therapeutics, 343, 468–478. https://doi.org/10.1124/jpet.112.198358.CrossRefPubMed

Titel: NRF2 in Cardiovascular Diseases: a Ray of Hope!
verfasst von: Ruju Vashi
Bhoomika M. Patel
Publikationsdatum: 25.11.2020
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 3/2021
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-020-10083-8

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

NRF2 in Cardiovascular Diseases: a Ray of Hope!

Abstract

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Retained Functionality of Atherosclerotic Human Arteries Following Photoactivated Linking of the Extracellular Matrix by Natural Vascular Scaffolding Treatment

Ex Vivo Model of Functional Mitral Regurgitation Using Deer Hearts

Left Ventricular Assist Devices for Acute Myocardial Infarct Size Reduction: Meta-analysis

p53-Dependent LincRNA-p21 Protects Against Proliferation and Anti-apoptosis of Vascular Smooth Muscle Cells in Atherosclerosis by Upregulating SIRT7 via MicroRNA-17-5p

Activation of AMP-Activated Protein Kinases Prevents Atrial Fibrillation

Adult Cardiomyocyte Proliferation: a New Insight for Myocardial Infarction Therapy

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie